Evidence map›Paper›PMID 41653179›Full record

ArticleJACC. Heart failure2026

Heart Replacement Therapy in Young Patients: A Comparative Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry.

Nir Uriel, Gabriel T Sayer, Boaz Elad, Justin A Fried, Jayant K Raikhelkar, Dor Lotan, Daniel J Goldstein, Ulrich P Jorde, Joseph C Cleveland, Mandeep R Mehra and 6 more

2 registry-linked trialsAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02224755 nacompletednot on this map

Thoratec Corporation MOMENTUM 3, Multi-center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3™ IDE Clinical Study Protocol

TypeinterventionalSponsorAbbott Medical DevicesRan2014 to 2019Enrolled1,028ConditionsAdvanced Refractory Left Ventricular Heart FailureArmsHeartMate 3 LVAS, HeartMate II LVAS
NCT02892955 nacompletednot on this map

Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3™ Continued Access Protocol: Post-Approval Continued Follow-up

TypeinterventionalSponsorAbbott Medical DevicesRan2016 to 2021Enrolled1,685ConditionsAdvanced Refractory Left Ventricular Heart FailureArmsHeartMate 3 LVAS
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Observational
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nir UrielColumbia University Irving Medical Center, New York, New York, USA.
Gabriel T SayerColumbia University Irving Medical Center, New York, New York, USA.
Boaz EladColumbia University Irving Medical Center, New York, New York, USA.
Justin A FriedColumbia University Irving Medical Center, New York, New York, USA.
Jayant K RaikhelkarColumbia University Irving Medical Center, New York, New York, USA.
Dor LotanColumbia University Irving Medical Center, New York, New York, USA.
Daniel J GoldsteinAlbert Einstein College of Medicine, New York, New York, USA; Montefiore Medical Center, Bronx, New York, USA.
Ulrich P JordeMontefiore Medical Center, Bronx, New York, USA.
Joseph C ClevelandSchool of Medicine, University of Colorado, Aurora, Colorado, USA.
Mandeep R MehraBrigham and Women's Hospital, Boston, Massachusetts, USA.
Stavros G DrakosSchool of Medicine and University of Utah Health, University of Utah, Salt Lake City, Utah, USA.
Katherine L WoodUniversity of California, Irvine Medical Center, Orange, California, USA.
John D HendersonAbbott Laboratories, Abbott Park, Illinois, USA.
Fei San LeeAbbott Laboratories, Abbott Park, Illinois, USA.
Manreet K KanwarDepartment of Medicine, University of Chicago, Chicago, Illinois, USA.
Kevin J ClerkinColumbia University Irving Medical Center, New York, New York, USA. Electronic address: kjc2142@cumc.columbia.edu.

Funding

Clinical and Metabolic Signature of Recovered Myocardium in Human Heart FailureR01HL135121 · NHLBI · UNIVERSITY OF UTAH · PI DRAKOS, STAVROS GEORGE · 2017 to 2021
$1.9M
Cellular Remodeling in Heart Failure and after LVAD UnloadingR01HL132067 · NHLBI · UNIVERSITY OF UTAH · PI DRAKOS, STAVROS GEORGE, SACHSE, FRANK BERND · 2017 to 2020
$1.5M
Identifying Novel Diagnostics and Mechanisms for Cardiac Allograft VasculopathyK23HL148528 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CLERKIN, KEVIN J · 2020 to 2024
$852k
CSRD VA I01 CX002291NHLBI NIH HHS K23 HL148528NHLBI NIH HHS R01 HL132067NHLBI NIH HHS R01 HL135121
6 · The paper itself

Abstract

backgroundYounger patients (18-49 years of age) with advanced heart failure (HF) face unique challenges in decision-making for advanced HF therapies. Although heart transplantation (HT) offers excellent survival, it is associated with finite graft longevity. The HeartMate 3 (HM3) left ventricular assist device (LVAD) has demonstrated promising outcomes, but direct comparisons with those listed for or undergoing HT in this age group remain limited.

objectivesThis study sought to compare survival and adverse event (AE) outcomes between younger patients receiving HM3 LVAD support and those listed for or undergoing HT.

methodsThe authors analyzed patients 18-49 years of age from the MOMENTUM 3 (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3) portfolio (HM3 cohort; n = 420) and the UNOS (United Network for Organ Sharing) registry (HT listing cohort; n = 1,955) (HT recipients; n = 1,176) from 2014-2018. Propensity score matching was performed to adjust for baseline differences. Outcomes included 2-year survival from time of treatment or time of listing, freedom from death or delisting for deterioration, and 1-year incidence of major AEs (ie, stroke, renal dysfunction, infection).

resultsAfter propensity score matching, 2-year survival from treatment was similar for HM3 and HT (88.7% vs 90.2%; HR: 1.18; P = 0.53). When comparing outcomes from time of transplant listing vs LVAD implantation, HM3 was associated with higher freedom from death compared with freedom from death or delisting due to deterioration in UNOS (90.1% vs 76.7%; HR: 0.38; P < 0.0001). AE analysis showed lower 1-year rates of renal dysfunction requiring dialysis (5.0% vs 10.4%; P = 0.016) and fewer infection-related hospitalizations (24.8% vs 34.2%; P = 0.012) in HM3 recipients, but a higher incidence of debilitating stroke (3.4% vs 0.3%; P = 0.027).

conclusionsContemporary data suggest that durable LVAD therapy may offer survival outcomes comparable to HT in adults <50 years of age. These findings support the consideration of an LVAD-first strategy as a viable initial approach to heart replacement therapy in appropriately selected patients. (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 Investigational Device Exemption [MOMENTUM 3 IDE]; NCT02224755) (MOMENTUM 3 Continued Access Protocol [MOMENTUM 3 CAP]; NCT02892955).

Indexed as

Heart-Assist DevicesHeart FailureHeart TransplantationRegistriesAdolescentAdultFemaleHumansMaleMiddle AgedPropensity ScoreSurvival RateTreatment OutcomeUnited StatesYoung Adultadvanced heart failureadverse event(s)heart transplantationleft ventricular assist devicepropensity score matchingsurvival

Identifiers

PMID41653179
PMCPMC12987674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.